HIV/AIDS

Funding: Featured Initiatives

Microbicide Innovation Program

Description: Supports focused microbicide innovation and development using the R21/R33 phased innovation and development mechanism. This is a milestone-driven program, wherein specific milestones are specified for the 2-year R21 portion of the award. If milestones are met and the research still meets program priorities and there are sufficient resources the award will be quickly transitioned to a 3-year R33.
Receipt dates: January 26, 2006
Awardees: TBD 

Integrated Preclinical Clinical Program for HIV Topical Microbicides

Description: This program is designed to support preclinical discovery and development up to exploratory Phase I clinical trials aimed at advancing a candidate microbicide or strategy to more advanced clinical trials. It is funded through a collaborative U19 mechanism.
Receipt dates: Not currently available
List of Awardees:

• Biosyn, Inc.
• Case Western Reserve University
• Magee-Womens Hospital
• UCLA
• Starpharma Pty LimitedOsel Inc.
• Weill Medical College of Cornell University

Microbicide Design and Development Teams (PDF)

Description: This program supports microbicide development from initial discovery through exploratory clinical testing (Phase I). It incorporates a commercial partner (private sector) in a multiproject environment under a cooperative agreement (U19) with NIH. It is focused on providing proof-of-concept for new microbicide strategies and approaches and supports critical path development of individual microbicides.
Receipt dates: September 23, 2004
Awardees: Starpharma Pty Limited